DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
Léna Rivard, MD
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Scott Solomon, MD
Mikhail Kosiborod, MD
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
Brian P. McDonough, MD, FAAFP
Barry Greenberg, MD
Neil Skolnik, MD
Karina Brown, BSN, RN
A Practical Guide to Prescribing in HF
Trina Huynh, PharmD
Melissa Mclenon, DNP, ACNP-BC
Level Up Your Skills: Tailoring Management of HF
Jessica Lin, MPAP
Optimizing Heart Failure Management
Partnering with Patients: Building Effective Communication and Support in HF Care
HF Management for Patients with Comorbid Conditions
How Artificial Sweeteners Could Be Linked to Heart Disease
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Wilson Tang, MD
What Is the Acute and Post Acute Risk of VTE in Acute Medically Ill Patients?
Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Case Time! VTE Prophylaxis Post Hip Replacement
Victor F. Tapson, MD
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
Scott Kaatz, DO, MSc, FACP, SFHM
Primary Prevention, Initial Treatment & Management of VTE, Secondary VTE Prevention Strategies
Bruce L. Davidson, MD, MPH
Deborah Siegal, MD, MSc, FRCPC
Alfonso J. Tafur, MD, MS, MBA, RPVI
Risk Assessment: Who’s Most Susceptible for a Secondary VTE Event?
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
What Do the Guidelines Suggest for Prophylaxis, and How Do We Implement?
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.